FREE

Secures Important Reimbursements

Aspira Women’s Health made two reimbursement announcements this week. On November 27, Aspira announced that the Centers for Medicare and Medicaid Services (CMS) approved the crosswalk of the fee to be paid to the company for OvaWatch to the fee paid historically for Ova1. Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning on January 1, 2024. “Crosswalking” refers to a process for setting the Medicare reimbursement rate for a new laboratory test by assigning the new code the same rate as a comparable test. On November 28, Aspira announced that California Medicaid (Medi-Cal) added Ova1Plus to its fee schedule. Aspira will be reimbursed at a rate of $897 for all Ova1Plus tests processed for Medi-Cal patients meeting applicable coverage requirements beginning immediately and going back to October 15, 2023. The California Department of Health Care Services, which is responsible for establishing policy and covered health care services for the Medi-Cal program, inclusive of both the fee-for-service and managed care delivery systems, has added the Ova1Plus CPT 81503 to its Provider Manual and fee schedule at the Medicare rate of $897.